Advertisement

Structural Determinants of Folate and Antifolate Membrane Transport by the Reduced Folate Carrier

  • Wei Cao
  • Larry H. Matherly
Protocol
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

Besides its important role in folate homeostasis, membrane transport is a critical determinant of the antitumor activities of antifolate therapeutics used in cancer chemotherapy, such as methotrexate (MTX) and an exciting new generation of antifolates typified by Tomudex and Pemetrexed. Further, impaired cellular uptake of antifolates is a frequent mode of drug resistance. The ubiquitously expressed transporter termed the reduced folate carrier (RFC) is the best characterized of the folate transport systems in mammalian cells. This chapter summarizes recent significant advances involving the molecular structure of the RFC protein, including its topology and glycosylation, as well as identification of its functionally and structurally important domains and amino acids. Insights into these features have been gleaned by epitope insertion and accessibility methods, and by mutating specific amino acids, through selection of antifolate resistant cells with impaired RFC function, and by site-directed mutagenesis. The recent expression of a functional “cysteine-less” human RFC has permitted the use of scanning cysteine mutagenesis and thiol modification techniques for mapping membrane topology and surface accessibilities, and for identifying functionally important domains in the RFC protein.

Key Words

Antifolate epitope insertion hydropathy analysis K562 human erythroleukemia cells L1210 murine leukemia cells 3-(N-Maleimidylpropionyl)biocytin methanethiosulfonate methotrexate mutagenesis: deletional mutagenesis: insertional mutagenesis: scanning cysteine mutagenesis: scanning glycosylation mutagenesis: site-directed photoaffinity labeling reduced folate carrier transmembrane domains 

References

  1. 1.
    Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000;71:121–138.PubMedCrossRefGoogle Scholar
  2. 2.
    Matherly LH, Goldman ID. Membrane transport of folates. Vitam Horm 2003;66: 403–456.PubMedCrossRefGoogle Scholar
  3. 3.
    Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Ann Rev Nutr 1999;19:91–122.CrossRefGoogle Scholar
  4. 4.
    Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985;28:77–100.PubMedCrossRefGoogle Scholar
  5. 5.
    Matherly LH. Molecular and cellular biology of the human reduced folate carrier. In: Moldave K, ed. Progress in Nucleic Acid Research and Molecular Biology, Vol. 67. San Diego: Harcourt/Academic Press; 2001:131–161.Google Scholar
  6. 6.
    Jansen G. Receptor-and carrier-mediated transport systems for folates and antifolates. Exploitation for folate chemotherapy and immunotherapy. In: Jackman AL, ed. Anticancer Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press, 1999:293–321.Google Scholar
  7. 7.
    Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29:3–17.PubMedGoogle Scholar
  8. 8.
    Schuetz JD, Matherly LH, Westin EH, Goldman ID. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate resistant murine L1210 leukemia cell line. J Biol Chem 1988;263:9840–9847.PubMedGoogle Scholar
  9. 9.
    Wong SC, McQuadeR, Proefke SA, Matherly LH. Human K562 transfectants expressing high levels of reduced folate carrier but exhibiting low transport activity. Biochem Pharmacol 1997;53:199–206.PubMedCrossRefGoogle Scholar
  10. 10.
    Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189–30198.PubMedCrossRefGoogle Scholar
  11. 11.
    Gong M, Yess J, Connolly T, et al. Molecular mechanism of antifolate transport deficiency in a methotrexate resistant MOLT-3 human leukemia cell line. Blood 1997;89:2494–2499.PubMedGoogle Scholar
  12. 12.
    Sadlish H, Williams FM, Flintoff WF. Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function. Biochem J 2002;364:777–786.PubMedCrossRefGoogle Scholar
  13. 13.
    Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981;41:4442–4452.Google Scholar
  14. 14.
    Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue methotrexate, in the L1210 leukemia cell. J Biol Chem 1968;243: 5007–5017.PubMedGoogle Scholar
  15. 15.
    Sirotnak FM, Kurita S, Hutchison DJ. On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia. Cancer Res 1968;28: 75–80.PubMedGoogle Scholar
  16. 16.
    Dixon KH, Lanpher BC, Chiu J, Kelley K, Cowan KH. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 1994;269:17–20.PubMedGoogle Scholar
  17. 17.
    Williams FMR, Murray RC, Underhill TM, Flintoff WF. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J Biol Chem 1994;269:5810–5816.PubMedGoogle Scholar
  18. 18.
    Sirotnak FM. Correlates of folate analog transport, pharmacokinetics, and selective antitumor action. Pharmacol Ther 1980;8:71–103.CrossRefGoogle Scholar
  19. 19.
    Sierra E E, Brigle KE, Spinella MJ, Goldman ID. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells—further evidence for a third route mediated at low pH. Biochem Pharmacol 1997;53:223–231.PubMedCrossRefGoogle Scholar
  20. 20.
    Kumar CK, Nguyen TT, Gonzales FB, Said HM. Comparison of intestinal folate carrier clone expressed in IEC-6 cells and in Xenopus oocytes. Am J Physiol 1998; 274:C289–C294.PubMedGoogle Scholar
  21. 21.
    Chiao JH, Roy K, Tolner B, Yang CH, Sirotnak FM. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem 1997;273: 11165–11170.Google Scholar
  22. 22.
    Horne DW, Reed KA. Transport of methotrexate into PC-3 human prostate cancer cells. Arch Biochem Biophys 2001;394:39–44PubMedCrossRefGoogle Scholar
  23. 23.
    White JC, Bailey BD, Goldman ID. Lack of stereospecificity at carbon 6 of methyltetrahydrofolate transport in Ehrlich ascites tumor cells. J Biol Chem 1978; 253:242–245.PubMedGoogle Scholar
  24. 24.
    Sirotnak FM, Chello PL, Moccio DM, et al. Stereospecificity at carbon 6 of formyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem Pharmacol 1979;28:2993–2997.PubMedCrossRefGoogle Scholar
  25. 25.
    Smith GK, Bigley JW, Dev IK, Duch DS, Ferone R, Pendergast W. GW1843: a potent, noncompetitive thymidylate synthase inhibitor; preclinical and preliminary clinical studies. In: Jackman AL, ed. Anticancer Development Guide: Antifolate Drugs in Cancer Therapy. Totowa, NJ: Humana Press; 1999:203–227.Google Scholar
  26. 26.
    Henderson GB, Zevely EM. Use of non-physiological buffer systems in the analysis of methotrexate transport in L1210 cells. Biochem Int 1983;6:507–515.PubMedGoogle Scholar
  27. 27.
    Yang C-H, Sirotnak FM, Dembo M. Interaction between anions and the reduced folate/methotrexate transport system in L1210 cell plasma membrane vesicles: directional symmetry and anion specificity for differential mobility of loaded and unloaded carrier. J Membr Biol 1984;70:285–292.Google Scholar
  28. 28.
    Henderson GB, Zevely EM. Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J Biol Chem 1984;259:1526–1531.PubMedGoogle Scholar
  29. 29.
    Goldman ID. A model system for the study of heteroexchange diffusion: methotrexate-folate interactions in L1210 leukemia and Ehrlich ascites tumor cells. Biochim Biophys Acta 1971;233:624–634.PubMedCrossRefGoogle Scholar
  30. 30.
    Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci 1971;186:400–422.PubMedCrossRefGoogle Scholar
  31. 31.
    Henderson GB, Zevely EM. Anion exchange mechanism for transport of methotrexate in L1210 cells. Biochem Biophys Res Commun 1981;99:163–169.PubMedCrossRefGoogle Scholar
  32. 32.
    Henderson GB, Zevely EM. Structural requirements for anion substrates of the methotrexate transport system of L1210 cells. Arch Biochem Biophys 1983;221: 438–446.PubMedCrossRefGoogle Scholar
  33. 33.
    Henderson GB, Zevely EM. Transport of methotrexate in L1210 cells: effect of ions on the rate and extent of uptake. Arch Biochem Biophys 1980;200: 149–155.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhao R, Gao F, Wang Y, Diaz GA, Gelb BD, Goldman ID. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 2001;276:1114–1118.PubMedCrossRefGoogle Scholar
  35. 35.
    Sirotnak FM, Moccio DM, Yang CH. A novel class of genetic variants of the L1210 cell up-regulated for folate analogue transport inward. Isolation, characterization, and degree of metabolic instability of the system. J Biol Chem 1984;259: 13139–13144.PubMedGoogle Scholar
  36. 36.
    Jansen G, Westerhof GR, Jarmuszewski MJ, Kathmann I, Rijksen G, Schornagel JH. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J Biol Chem 1990; 265:18272–18277.PubMedGoogle Scholar
  37. 37.
    Matherly LH, Czajkowski CA, Angeles SM. Identification of a highly glycosylated methotrexate membrane carrier in K562 erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res 1991;51: 3420–3426.PubMedGoogle Scholar
  38. 38.
    Yang CH, Pain J, Sirotnak FM. Alteration of folate analogue transport inward after induced maturation of HL-60 leukemia cells. Molecular properties of the transporter in an overproducing variant and evidence for down-regulation of its synthesis in maturating cells. J Biol Chem 1992;267:6628–6634.PubMedGoogle Scholar
  39. 39.
    Henderson GB, Grzelakowska-Sztabert B, Zevely EM, Huennekens FM. Binding properties of the 5-methyltetrahydrofolate/methotrexate transport system in L1210 cells. Arch Biochem Biophys 1980;202:244–249.Google Scholar
  40. 40.
    Henderson GB, Zevely EM, Huennekens FM. Photoinactivation of the methotrexate transpoprt system of L1210 cells by 8-azidoadenosine-5′-monophosphate. J Biol Chem 1979;254:9973–9975.PubMedGoogle Scholar
  41. 41.
    Henderson GB, Zevely EM. Functional correlations between the methotrexate and general anion transport systems of L1210 cells. Biochem Int 1982;4:493–502.Google Scholar
  42. 42.
    Henderson GB, Zevely EM, Huennekens FM. Irreversible inactivation of the methotrexate transport systems in L1210 cells by carbodiimide activated substrates. J Biol Chem 1980;255:4826–4833.Google Scholar
  43. 43.
    Jansen G, Westerhof GR, Rijksen G, Schornagel JH. Interaction of N-hydroxy-(sulfo)succinimide active esters with the reduced folate/methotrexate transport system from human leukemic CCRF-CEM cells. Biochim Biophys Acta 1989;875: 266–270.Google Scholar
  44. 44.
    Henderson GB, Zevely EM. Affinity labeling of the 5-methyltetrahydrofolate/ methotrexate transport protein of L1210 cells by treatment with an N-hydroxy-succinimide ester of [3H]methotrexate. J Biol Chem 1984;259:4558–4562.PubMedGoogle Scholar
  45. 45.
    Freisheim JH, Ratnam M, McAlinden TP, et al. Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines. Adv Enzyme Regul 1992;32:17–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhao R, Gao F, Liu L, Goldman ID. The reduced folate carrier in L1210 murine leukemia cells Is a 58 kDa protein. Biochim Biophys Acta 2000;1466:7–10.PubMedCrossRefGoogle Scholar
  47. 47.
    Price EM, Sams L, Harpring KM, Kempton RJ, Freisheim JH. Photoaffinity analogues of methotrexate as probes for dihydrofolate reductase structure and function. Biochem Pharmacol 1986;35:4341–4343.PubMedCrossRefGoogle Scholar
  48. 48.
    Underhill TM, Williams FMR, Murray RC, Flintoff WF. Molecular cloning of a gene involved in methotrexate uptake by DNA-mediated gene transfer. Somat Cell Mol Genet 1992;18,337–349.PubMedCrossRefGoogle Scholar
  49. 49.
    Moscow JA, Gong MK, He R, et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res 1995;55: 3790–3794.PubMedGoogle Scholar
  50. 50.
    Prasad PD, Ramamoorthy S, Leibach FH, Ganapathy V. Molecular cloning of the human placental folate transporter. Biochem Biophys Res Commun 1995;206; 681–687.PubMedCrossRefGoogle Scholar
  51. 51.
    Williams FMR, Flintoff WF. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J Biol Chem 1995;270: 2987–2992.PubMedCrossRefGoogle Scholar
  52. 52.
    Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem 1995;270: 17468–17475.PubMedCrossRefGoogle Scholar
  53. 53.
    Nguyen TT, Dyer DL, Dunning DD, Rubin SA, Grant KE, Said HM. Human intestinal folate transport: cloning, expression, and distribution of complementary RNA. Gastroenterology 1997;112:783–791.PubMedCrossRefGoogle Scholar
  54. 54.
    Brigle KE, Spinella MJ, Sierra EE, Goldman ID. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem 1995;270:22974–22979.PubMedCrossRefGoogle Scholar
  55. 55.
    Wong SC, Zhang L, Proefke SA, Matherly LH. Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier. Biochim Biophys Acta 1998;1375:6–12.PubMedCrossRefGoogle Scholar
  56. 56.
    Kumar CK, Nguyen TT, Gonzales FB, Said HM. Comparison of intestinal folate carrier clone expressed in IEC-6 cells and in Xenopus oocytes. Am J Physiol 1998;274:C289–C294.PubMedGoogle Scholar
  57. 57.
    Rajgopal A, Sierra EE, Zhao R, Goldman ID. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 2001;281:C1579–C1586.PubMedGoogle Scholar
  58. 58.
    Hoffman K, Stoffel W. TMBASE-A database of membrane spanning protein segments. Biol Chem Hoppe Seyler 1993;374:166.Google Scholar
  59. 59.
    Ferguson PL, Flintoff WF. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J Biol Chem 1999;274: 16269–18278.PubMedCrossRefGoogle Scholar
  60. 60.
    Liu X, Matherly LH. Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochim Biophys Acta 2002;1564:333–342.PubMedCrossRefGoogle Scholar
  61. 61.
    Popov M, Tam LY, Li J, Reithmeier RA. Mapping the ends of transmembrane segments in a polytopic membrane protein. Scanning N-glycosylation mutagenesis of extracytosolic loops in the anion exchanger, Band 3. J Biol Chem 1997;272: 18325–18332.PubMedCrossRefGoogle Scholar
  62. 62.
    Wong SC, Zhang L, Witt TL, Proefke SA, Bhushan A, Matherly LH. Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J Biol Chem 1999;274:10388–10394.PubMedCrossRefGoogle Scholar
  63. 63.
    Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cell lines. Biochem J 2002;367:741–750.PubMedCrossRefGoogle Scholar
  64. 64.
    Zhao R, Assaraf YG, Goldman ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998;273: 19065–19071.PubMedCrossRefGoogle Scholar
  65. 65.
    Gifford AJ, Haber M, Witt TL, et al. Role of the E45K reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells. Leukemia 2002;16: 2379–2387.PubMedCrossRefGoogle Scholar
  66. 66.
    Drori S, Jansen G, Mauritz R, Peters GJ, Assaraf YG. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Biol Chem 2000;275:30855–30863.PubMedCrossRefGoogle Scholar
  67. 67.
    Zhao R, Gao F, Wang PJ, Goldman ID. Role of the amino acid 45 residue in reduced folate carrier function and ion-dependent transport as characterized by site-directed mutagenesis. Mol Pharmacol 2000;57:317–323.PubMedGoogle Scholar
  68. 68.
    Zhao R, Assaraf YG, Goldman ID. A reduced carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J Biol Chem 1998;273:7873–7879.PubMedCrossRefGoogle Scholar
  69. 69.
    Yang R, Sowers R, Mazza B, et al. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003;9:837–844.PubMedGoogle Scholar
  70. 70.
    Tse A, Brigle K, Taylor SM, Moran RG. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. J Biol Chem 1998;273:25953–25960.PubMedCrossRefGoogle Scholar
  71. 71.
    Zhao R, Gao F, Goldman ID. Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. Biochem Pharmacol 1999;58:1615–1624.PubMedCrossRefGoogle Scholar
  72. 72.
    Roy K, Tolner B, Chiao JH, Sirotnak FM. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. J Biol Chem 1998;273:2526–2531.PubMedCrossRefGoogle Scholar
  73. 73.
    Zhao R, Gao F, Babani S, Goldman ID. Sensitivity of 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier. Clin Cancer Res 2000;6:3304–3311.PubMedGoogle Scholar
  74. 74.
    Liu XY, Matherly LH. Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association. Biochem J 2001;358:511–516.PubMedCrossRefGoogle Scholar
  75. 75.
    Sharina IG, Zhao R, Wang Y, Babani S, Goldman ID. Mutational analysis of the functional role of conserved arginine and lysine residues in transmembrane domains of the murine reduced folate carrier. Mol Pharmacol 2001;59:1022–1028.PubMedGoogle Scholar
  76. 76.
    Sadlish H, Williams FM, Flintoff WF. Functional role of arginine 373 in substrate translocation by the reduced folate carrier. J Biol Chem 2002;277: 42105–42112.PubMedCrossRefGoogle Scholar
  77. 77.
    Witt TL, Matherly LH. Identification of lysine-411 in the human reduced folate carrier as an important determinant of substrate selectivity and carrier function by systematic site directed mutagenesis. Biochim Biophys Acta 2002;1567: 56–62.PubMedCrossRefGoogle Scholar
  78. 78.
    Marchant JS, Subramanian VS, Parker I, Said HM. Intracellular trafficking and membrane targeting mechanisms of the human reduced folate carrier in mammalian epithelial cells. J Biol Chem 2002;277:33325–33333.PubMedCrossRefGoogle Scholar
  79. 79.
    Sadlish H, Williams FM, Flintoff WF. Cytoplasmic domains of the reduced folate carrier are essential for trafficking, but not function. Biochem J 2002;364:777–786.PubMedCrossRefGoogle Scholar
  80. 80.
    Sharina IG, Zhao R, Wang Y, Babani S, Goldman ID. Role of the C-terminus and the long cytoplasmic loop in reduced folate carrier expression and function. Biochem Pharmacol 2002;63:1717–1724.PubMedCrossRefGoogle Scholar
  81. 81.
    Liu XY, Witt TL, Matherly LH. Restoration of high level transport activity by human reduced folate carrier/ThTr1 chimeric transporters: role of the transmem-brane domain 6/7 linker region in reduced folate carrier function. Biochem J 2003;369:31–37.PubMedCrossRefGoogle Scholar
  82. 82.
    Barril X, Aleman C, Orozco M, Luque FJ. Salt bridge interactions: stability of the ionic and neutral complexes in the gas phase, in solution, and in proteins. Proteins 1998;32:67–79.PubMedCrossRefGoogle Scholar
  83. 83.
    Dunten RL, Sahin-Toth M, Kaback HR. Role of the charge pair aspartic acid-237-lysine-358 in the lactose permease of Escherichia coli. Biochemistry 1993;32: 3139–3145.PubMedCrossRefGoogle Scholar
  84. 84.
    Merickel A, Kaback HR, Edwards RH. Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. J Biol Chem 1997;272:5403–5408.PubMedCrossRefGoogle Scholar
  85. 85.
    Zhao R, Wang Y, Gao F, Goldman ID. Residues 45 and 404 in the murine reduced folate carrier may interact to alter carrier binding and mobility. Biochim Biophys Acta 2003;1613:49–56.PubMedCrossRefGoogle Scholar
  86. 86.
    Karlin A, Akabas MH. Substituted-cysteine accessibility method. Methods Enzymol 1998;293:123–145.PubMedCrossRefGoogle Scholar
  87. 87.
    Frillingos S, Sahin-Toth M, Wu J, Kaback HR. Cys-scanning mutagenesis: a novel approach to structure function relationships in polytopic membrane proteins. FASEB J 1998;12:1281–1299.PubMedGoogle Scholar
  88. 88.
    Loo TW, Clarke DM. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol modification techniques. Biochim Biophys Acta 1999;1461:315–325.PubMedCrossRefGoogle Scholar
  89. 89.
    Loo TW, Clarke DM. Membrane topology of a cysteine-less mutant of human P-glycoprotein. J Biol Chem 1995;270:843–848.PubMedCrossRefGoogle Scholar
  90. 90.
    Nicoll DA, Ottolia M, Lu L, Lu Y, Philipson KD. A new topological model of the cardiac sarcolemmal Na+-Ca2+ exchanger. J Biol Chem 1999;274:910–917.PubMedCrossRefGoogle Scholar
  91. 91.
    Hu YK, Kaplan JH. Site-directed chemical labeling of extracellular loops in a membrane protein. The topology of the Na,K-ATPase alpha-subunit. J Biol Chem 2000;275:19185–19191.PubMedCrossRefGoogle Scholar
  92. 92.
    Dodd JR, Christie DL. Cysteine 144 in the third transmembrane domain of the creatine transporter is located close to a substrate-binding site. J Biol Chem 2001;276:46983–46988.PubMedCrossRefGoogle Scholar
  93. 93.
    Loo TW, Clarke DM. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. J. Biol. Chem 2000;275:39272–39278.PubMedCrossRefGoogle Scholar
  94. 94.
    Slotboom DJ, Konings WN, Lolkema JS. Cysteine-scanning mutagenesis reveals a highly amphipathic, pore-lining membrane-spanning helix in the glutamate transporter GltT. J Biol Chem 2001;276:10775–10781.PubMedCrossRefGoogle Scholar
  95. 95.
    Kwaw I, Zen KC, Hu Y, Kaback HR. Site-directed sulfhydryl labeling of the lactose permease of Escherichia coli: helices IV and V that contain the major determinants for substrate binding. Biochemistry 2001;40:10491–10499.PubMedCrossRefGoogle Scholar
  96. 96.
    Zeng FY, Hopp A, Soldner A, Wess J. Use of a disulfide cross-linking strategy to study muscarinic receptor structure and mechanisms of activation. J Biol Chem 1999;274:16629–16640.PubMedCrossRefGoogle Scholar
  97. 97.
    Loo TW, Clarke DM. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol cross-linking compounds as molecular rulers. J Biol Chem 2001;276:36877–36880.PubMedCrossRefGoogle Scholar
  98. 98.
    Cao W, Matherly LH. Characterization of a cysteine-less human reduced folate carrier: localization of a substrate binding domain by cysteine scanning mutagenesis and cysteine accessibility methods. Biochem J 2003;374:27–36.PubMedCrossRefGoogle Scholar
  99. 99.
    Saier MH Jr, Beatty JT, Goffeau A, et al. The major facilitator superfamily. J Mol Microbiol Biotechnol 1999;1:257–279.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Wei Cao
    • 1
  • Larry H. Matherly
    • 1
  1. 1.Developmental Therapeutics, Karmanos Cancer Institute and Department of PharmacologyWayne State University School of MedicineDetroit

Personalised recommendations